United Therapeutics (NASDAQ: UTHR)
United Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
United Therapeutics Company Info
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
News & Analysis
United Therapeutics Earnings Soared in Q1
The biotech beat estimates as sales of its top drug, Tyvaso, continued to grow.
Why United Therapeutics Blasted 14% Higher Today
Every one of the company's products booked a revenue gain in Q2.
This Pharma Can Breathe New Life Into Your Portfolio
Will future Tyvaso revenue growth push United Therapeutics to new heights?
How United Therapeutics Trounced Wall Street's Q3 Estimates
Revenue and earnings fell from the prior-year period, but the drugmaker blew past analysts' estimates thanks to a combination of factors.
Here's Why United Therapeutics Fell 18.1% in May
The stock has now fallen nearly 30% since the end of March.
Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
Is MannKind Corporation Stock a Buy?
A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.
The Probable Reason Why MannKind Corporation Is Rallying Again
Shares soar for the second day in a row. What can explain the bullish move?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.